ANI Pharmaceuticals Statistics
Want to see ANIP full AI Analyst Report?
ANI Pharmaceuticals (ANIP) Stock Statistics & Valuation Metrics
Total Valuation
ANI Pharmaceuticals has a market cap or net worth of $1.62B. The enterprise value is $1.75B.
- Market Cap
- $1.62B
- Enterprise Value
- $1.75B
Share Statistics
ANI Pharmaceuticals has 22,718,931 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 22,718,931
- Owned by Insiders
- 7.83%
- Owned by Institutions
- 76.07%
Financial Efficiency
ANI Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 5.63%.
- Return on Equity (ROE)
- 0.14
- Return on Assets (ROA)
- 0.05
- Return on Invested Capital (ROIC)
- 5.63%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 910.69K
- Profits Per Employee
- 80.76K
- Employee Count
- 970
- Asset Turnover
- 0.61
- Inventory Turnover
- 3.02
Valuation Ratios
The current PE Ratio of ANI Pharmaceuticals is 13.79. ANI Pharmaceuticals’s PEG ratio is 0.07.
- PE Ratio
- 13.79
- PS Ratio
- 1.56
- PB Ratio
- 2.38
- Price to FCF
- 9.15
- Price to Operating Cash Flow
- 6.61
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 883.37M and earned 78.34M in profits. Earnings per share was 3.50.
- Revenue
- 883.37M
- Gross Profit
- 450.64M
- Operating Income
- 81.23M
- Pretax Income
- 95.79M
- Net Income
- 78.34M
- EBITDA
- 207.27M
- Earnings Per Share (EPS)
- 3.50
Cash Flow
In the last 12 months, operating cash flow was 229.20M and capital expenditures -51.74M, giving a free cash flow of 177.46M billion.
- Operating Cash Flow
- 229.20M
- Free Cash Flow
- 177.46M
- Free Cash Flow per Share
- 8.37
Dividends & Yields
ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.79%
- Earnings Yield
- 7.69%
Stock Price Statistics
- Beta
- 0.50
- 52-Week Price Change
- -15.51%
- 50-Day Moving Average
- 72.33
- 200-Day Moving Average
- 77.03
- Relative Strength Index (RSI)
- 49.71
- Average Volume (3m)
- 409.60K
Important Dates
ANI Pharmaceuticals upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
ANI Pharmaceuticals as a current ratio of 2.71, with Debt / Equity ratio of 60.14%
- Current Ratio
- 2.71
- Quick Ratio
- 2.19
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- 0.19
- Interest Coverage Ratio
- 4.05
Taxes
In the past 12 months, ANI Pharmaceuticals has paid 17.45M in taxes.
- Income Tax
- 17.45M
- Effective Tax Rate
- 0.18
Enterprise Valuation
ANI Pharmaceuticals EV to EBITDA ratio is 5.62, with an EV/FCF ratio of 8.58.
- EV to Sales
- 1.46
- EV to EBITDA
- 5.62
- EV to Free Cash Flow
- 8.58
- EV to Operating Cash Flow
- 6.64
Balance Sheet
ANI Pharmaceuticals has $436.35M in cash and marketable securities with $297.68M in debt, giving a net cash position of $138.67M billion.
- Cash & Marketable Securities
- $436.35M
- Total Debt
- $297.68M
- Net Cash
- $138.67M
- Net Cash Per Share
- $6.10
- Tangible Book Value Per Share
- $6.67
Margins
Gross margin is 67.76%, with operating margin of 17.26%, and net profit margin of 11.22%.
- Gross Margin
- 67.76%
- Operating Margin
- 17.26%
- Pretax Margin
- 15.16%
- Net Profit Margin
- 11.22%
- EBITDA Margin
- 26.01%
- EBIT Margin
- 18.07%
Analyst Forecast
The average price target for ANI Pharmaceuticals is $105.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $105.14
- Price Target Upside
- 47.18% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 25.94%
- EPS Growth Forecast
- 203.25%
Scores
- Smart Score
- 5
- AI Score
- 72
